Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.

Small GTPases - 3 Jul 2017

Kitai Hidenori, Ebi Hiromichi

Abstract excerpt

KRAS is frequently mutated in a variety of cancers including lung cancer. Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of KRAS, blocking this pathway with MEK inhibitors is relatively ineffective. One major contributor to limited efficacy is attributed to the reactivation of MAPK signal following MEK inhibition by multiple feedback mechanisms. In a recent study, we have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelial-Mesenchymal Transition
Share to ERBB3 gene
Share to FGFR1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Lung Neoplasms

Share to Mitogen-Activated Protein Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 27392325
DOI: 10.1080/21541248.2016.1210369
PMCID: PMC5584737

Genes

KRAS
FGFR1
ERBB3
FRS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.PMID 27392325Read ↗

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

The ERBB network facilitates KRAS-driven lung tumorigenesisSemantic proximity Read ↗

Targeting KRAS mutant lung cancer: light at the end of the tunnel.Semantic proximity Read ↗

The ERBB network facilitates KRAS-driven lung tumorigenesis.Semantic proximity Read ↗

Targeting the MAPK Pathway in KRAS-Driven Tumors.Semantic proximity Read ↗

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.Semantic proximity Read ↗

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.Semantic proximity Read ↗

Targeting the MAPK Pathway in RAS Mutant Cancers.Semantic proximity Read ↗

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Semantic proximity Read ↗

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.Semantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.